Satellos Bioscience Inc. announced positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration. The preclinical data presented show the broad potential of SAT-3247 to improve skeletal muscle function as has been demonstrated in three mouse models of muscle degeneration: mdx model of Duchenne muscular dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSHD), and a muscle injury model in wildtype mice. In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | +9.09% | -7.69% | +11.63% |
Mar. 27 | Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 27 | Satellos Bioscience Announces FY 2023 Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.63% | 39.55M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.73% | 22.15B | |
-17.37% | 21.02B | |
-8.42% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MSCL Stock
- News Satellos Bioscience Inc.
- Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference